<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客研究院 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-27T13:20:32+08:00</updated>
  <subtitle>独立报告、专业分析、深度解读</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>凯信远达：专注血液肿瘤，期待扭亏为盈｜公司</title>
    <updated>2020-11-27T10:02:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-27:/s/dCveSKY6M-DsxgYpGJZxCg</id>
    <link href="https://mp.weixin.qq.com/s/dCveSKY6M-DsxgYpGJZxCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NK细胞是肿瘤免疫下一个风口？被赛诺菲收购的Kiadis是什么来头？ | 公司分析</title>
    <updated>2020-11-20T02:50:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/4-iCYw43bmtqDtz5z2-sVA</id>
    <link href="https://mp.weixin.qq.com/s/4-iCYw43bmtqDtz5z2-sVA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>11月21日客论直播 ∣ 新法规形势下的国际多中心临床避坑指南</title>
    <updated>2020-11-18T08:40:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/AJu_WMGz9vk976TGh20qYw</id>
    <link href="https://mp.weixin.qq.com/s/AJu_WMGz9vk976TGh20qYw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品临床综合评价的变与不变 | 观点·政策</title>
    <updated>2020-11-13T10:44:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/mi999Ey-QGI8x0gdqvA5kg</id>
    <link href="https://mp.weixin.qq.com/s/mi999Ey-QGI8x0gdqvA5kg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>互联网+医保：线上医疗加速度 | 观点·政策</title>
    <updated>2020-11-06T10:53:33+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-06:/s/J69s5wg6HOoc1aQ71yHnng</id>
    <link href="https://mp.weixin.qq.com/s/J69s5wg6HOoc1aQ71yHnng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>SQZ Biotech：专注细胞挤压技术 | 公司分析</title>
    <updated>2020-10-29T21:35:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/xOOy87zmZ6jhy1kPRgcbJg</id>
    <link href="https://mp.weixin.qq.com/s/xOOy87zmZ6jhy1kPRgcbJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>委托生产，MAH和受托方的质量责任有哪些？ | 观点</title>
    <updated>2020-10-23T09:51:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-23:/s/-sF9tq6lFafhOiU8l-i_Dw</id>
    <link href="https://mp.weixin.qq.com/s/-sF9tq6lFafhOiU8l-i_Dw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>12款新药将在年底前获得FDA批准，有哪些？ | 产品分析</title>
    <updated>2020-10-20T11:10:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-20:/s/M2ozSMJLcsuxbawtW3tPhw</id>
    <link href="https://mp.weixin.qq.com/s/M2ozSMJLcsuxbawtW3tPhw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>赛生药业单一支柱产品背后的出路 | 公司分析</title>
    <updated>2020-10-12T21:56:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-12:/s/kmF404azXuMlbNJ-FsgETQ</id>
    <link href="https://mp.weixin.qq.com/s/kmF404azXuMlbNJ-FsgETQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Germany’s Merck Brings Next Wave Of Oncology Blockbusters</title>
    <updated>2020-10-08T20:48:31+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-08:/s/qXJ9aZ8rpBsFm8D8HVumMw</id>
    <link href="https://mp.weixin.qq.com/s/qXJ9aZ8rpBsFm8D8HVumMw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>